Skip to main content
ROIV
NASDAQ Life Sciences

Q1 Report Highlights Strong Cash Position, Moderna Settlement Payment, and Pipeline Progress

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$35.1
Mkt Cap
$24.995B
52W Low
$10.9
52W High
$37
52W Position info
222% above low
Off High info
5.1% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

ROIV has more than doubled off its 52-week low of $10.9.

Summary

Roivant Sciences reported a strong Q1, boosted by a $950 million Moderna settlement payment, bringing total liquidity to over $4.7 billion and extending its cash runway. The company also continued share repurchases and advanced its pipeline, despite an executive filing a pre-planned stock sale.


Key Events · Earnings and Guidance · ROIV

  • Moderna Settlement Payment Received

    Received a $950 million fixed payment on July 8, 2026, from the global patent infringement settlement with Moderna. An additional contingent payment of up to $1.3 billion is possible.

  • Strong Cash Position & Runway

    Reported $3.8 billion in cash, cash equivalents, and marketable securities as of June 30, 2026, which, combined with the Moderna payment, supports a cash runway into profitability.

  • Share Repurchase Program Active

    Repurchased $208.7 million in common shares during Q1 2026, with approximately $681.7 million remaining authorized for future repurchases.

  • Pipeline Progress & Upcoming Catalysts

    Advanced key pipeline assets, including an anticipated FDA decision for brepocitinib in dermatomyositis in Q3 2026, and ongoing registrational trials for IMVT-1402 and mosliciguat.


Analysis · ROIV · Life Sciences

Roivant Sciences' Q1 report reveals a significantly strengthened financial position, primarily driven by the receipt of a $950 million fixed payment from the Moderna patent settlement. This payment, along with existing cash, cash equivalents, and marketable securities totaling $3.8 billion as of June 30, 2026, provides a robust cash runway. The company also continued its share repurchase program, buying back $208.7 million in shares during the quarter. Operationally, Roivant reported progress across its key pipeline assets, including an upcoming FDA decision for brepocitinib in Q3 2026 and ongoing trials for IMVT-1402 and mosliciguat. While the company continues to incur net losses, the improved liquidity and pipeline advancements are key positives. A notable counter-signal is the disclosure of a 10b5-1 trading plan by President and Immunovant CEO Eric Venker to sell up to 1.78 million shares over the next year, which is a pre-planned sale and not an immediate transaction.

How filings like this one have moved

In the 30 days to Nov 2, 2026, 40.4% of the 1069 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ROIV was trading at $35.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25B. The 52-week trading range was $10.90 to $37.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ROIV - Latest Insights

ROIV
Oct 21, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.20
Real-time Price: $36.15 info
Change: -$0.055 (-0.15%) info
Market Cap: $26.108B info
ROIV
Oct 21, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $36.60
Real-time Price: $36.15 info
Change: -$0.455 (-1%) info
Market Cap: $26.108B info
ROIV
Sep 23, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $37.74
Real-time Price: $36.15 info
Change: -$1.59 (-4%) info
Market Cap: $26.108B info
ROIV
Sep 14, 2026, 7:22 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $40.95
Real-time Price: $36.15 info
Change: -$4.81 (-12%) info
Market Cap: $26.108B info
ROIV
Sep 08, 2026, 9:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $41.29
Real-time Price: $36.15 info
Change: -$5.14 (-12%) info
Market Cap: $26.108B info